Teva Executes Underwriting Agreement for $4.9B Multi-Currency Senior Notes Offering
TEVA has more than doubled off its 52-week low of $18.21.
Summary
Teva executed the underwriting agreement for its $4.9B equivalent senior notes offering, finalizing pricing and expanding conditional redemptions of higher-coupon debt.
Key Events · Financing and Capital Events · TEVA
-
Underwriting Agreement Executed
Teva and its Dutch finance subsidiaries signed the underwriting agreement on September 9, 2026 with BNP PARIBAS, Citigroup, Goldman Sachs, and J.P. Morgan as representatives.
-
Final Pricing Across Five Tranches
2033 Euro Notes priced at 98.756%, 2036 Euro Notes at 98.327%, 2034 USD Notes at 98.659%, 2037 USD Notes at 98.520%, and 2032 USD Notes at 98.993% of principal.
-
Expanded Conditional Redemptions
Teva added a conditional redemption notice for all 8.125% USD Sustainability-Linked Senior Notes due 2031 and reduced the 4.375% Sustainability-Linked Senior Notes due 2030 redemption from €1,250M to €1,150M.
-
Refinancing High-Coupon Debt
Proceeds will fund redemptions of 6.750% notes due 2028, 7.875% and 7.375% sustainability-linked notes due 2029, and up to $450M of 4.750% notes due 2027.
Analysis · TEVA · Life Sciences
Teva formalized the underwriting agreement for its $4.9 billion equivalent senior notes offering, locking in exact pricing across five tranches and expanding its conditional redemption plans. The deal refinances high-coupon debt — including 6.750% notes due 2028 and 7.875% sustainability-linked notes due 2029 — with lower-rate paper, reducing interest expense. The additional redemption notice for 8.125% notes due 2031 and the reduction of the 2030 redemption from €1.25B to €1.15B are new details that shift the liability management picture. Settlement is expected September 16, 2026.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TEVA was trading at $37.09 on NYSE in the Life Sciences sector, with a market capitalization of approximately $42.4B. The 52-week trading range was $18.21 to $38.37. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.